NCT06745063RecruitingPhase 2
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 17 Dec 2024
- Start date
- 30 May 2025
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- VA Office of Research and Development
- Diseases
- Obesity
- NCT number
- NCT06745063
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 30 May 2025 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of GLP-1 analogs or SGLT2 inhibitors
- Use of hormone replacement therapy
- Use of pharmacological therapy for weight loss
- Change in anti-hypertensive medication regimen (if in use) during the last 90 days
Other illness
- Diabetes mellitus
- Uncontrolled hypertension (\>180/90 millimeters of mercury) or systolic \<100 millimeters of mercury at screening visit
- Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke
- Diagnosis of chronic kidney disease
- Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
- History of hypersensitivity to nitrates
- History of ketoacidosis
- History of recurrent UTIs or mycotic genital infections
Other
- Unable to provide consent
- Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
- Body weight changes \>10% within the past 6 months
- Use of anticoagulants
- Pregnancy
Who the study is looking for
- Body mass index (BMI) 30-45 kilograms per square meter (kg/m2)
- 30-60 years of age at randomization
- Evidence of arterial stiffening (defined as Carotid femoral PWV\>age-predicted) at screening visit (PMID: 20530030), or presence of Stage I hypertension or higher (PMID: 30354655), or current use of antihypertensive agents
Age in the registry: 30 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Harry S. Truman Memorial, Columbia, MO Coordinator of this site? Confirm its status | Columbia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.